California Doc Loses DEA Badge: No More Controlled Drug Handling
Published Date: 6/26/2025
Notice
Summary
Dr. Bohdan Olesnicky from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration starting in 2025. This means he can’t legally prescribe or handle certain drugs anymore, affecting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked July 28, 2025
The Drug Enforcement Administration revoked Bohdan Olesnicky, M.D.'s DEA Certificate of Registration No. FO0628391, effective July 28, 2025. Because Dr. Olesnicky surrendered his California medical license on December 5, 2023, he is not authorized to prescribe or handle controlled substances in California and may not legally dispense those drugs.
Pending DEA Applications Denied in California
The Order also denies any pending applications by Bohdan Olesnicky, M.D., to renew or modify Certificate of Registration No. FO0628391 and denies any other pending applications for additional DEA registration in California. This denial is part of the same Order that takes effect July 28, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-11496, Agency Information Collection Activities; Proposed Collection; Comment Request; Office of Foreign Assets Control Reporting, Procedures and Penalties Regulations Sanctions Reconsideration Portal
The Treasury’s Office of Foreign Assets Control (OFAC) wants to add a new online portal for people to ask for sanctions reconsideration, making the process easier and cutting down on paperwork. This affects anyone dealing with OFAC sanctions rules and invites public comments by August 25, 2025. No big costs are expected, just smoother reporting and clearer procedures.
Next: 2025-11730, Agency Information Collection Activities; Notice and Request for Comment; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery
The National Highway Traffic Safety Administration (NHTSA) wants to restart a program that collects feedback from the public about how well they deliver their services. This helps them improve without spending extra money or time on big surveys. If you have thoughts, you can share them by August 25, 2025, so NHTSA can keep making things better for everyone.